Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUGlobeNewsWire • 12/22/23
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $500,000 to Contact the FirmAccesswire • 12/22/23
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010GlobeNewsWire • 12/19/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)PRNewsWire • 12/18/23
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 12/17/23
ROSEN, A RANKED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 12/11/23
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $500,000 to Contact the FirmAccesswire • 12/11/23
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Outlook Therapeutics, Inc. (OTLK) InvestorsBusiness Wire • 12/07/23
OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their OptionsPRNewsWire • 12/05/23
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in Outlook Therapeutics, Inc. with Losses In Excess of $500,000 to Contact the FirmAccesswire • 12/04/23
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 12/03/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $100,000 to Contact the FirmAccesswire • 12/03/23
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 12/01/23
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their OptionsPRNewsWire • 11/30/23
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $500,000 to Contact the FirmAccesswire • 11/30/23
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 11/28/23
CLASS ACTION REMINDER: Berger Montague Advises Outlook Therapeutics, Inc. (NASDAQ: OTLK) Investors to Inquire About a Securities Fraud Lawsuit by January 2, 2024PRNewsWire • 11/27/23
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010GlobeNewsWire • 11/27/23
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024PRNewsWire • 11/27/23
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 11/26/23
OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Business Wire • 11/21/23
Outlook Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Outlook TherapeuticPRNewsWire • 11/21/23
OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their OptionsPRNewsWire • 11/18/23
